Lipid management in people with peripheral artery disease

Jonathan Golledge, Natalie C. Ward, Gerald F. Watts

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: To summarize recent data on the role of dyslipidaemia and the benefit from managing this in people with disease of the abdominal aorta and its peripheral branches (peripheral artery disease, PAD). RECENT FINDINGS: Findings from the Further Cardiovascular Outcomes Research with Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial demonstrate the benefit of intensely lowering low-density lipoprotein-cholesterol (LDL-c) in people with PAD to substantially reduce the incidence of major cardiovascular events (MACE; myocardial infarction, stroke or cardiovascular death) and major adverse limb events (MALE). Despite the evidence of substantial benefits from lowering LDL-c, the uptake of drug therapies to lower LDL-c remains sub-optimal in people with PAD. SUMMARY: Effective methods to educate physicians and patients on best medical management are needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid therapies for PAD-specific problems like abdominal aortic aneurysm progression and walking impairment. Other novel lipid therapies, such as those that lower lipoprotein (a), maybe particularly beneficial to people with PAD given the evidence indicating high concentrations in this population and the high incidence of MACE in these individuals.

Original languageEnglish
Pages (from-to)470-476
Number of pages7
JournalCurrent Opinion in Lipidology
Volume30
Issue number6
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Peripheral Arterial Disease
LDL Cholesterol
Lipids
Myocardial Infarction
Lipoprotein(a)
Abdominal Aorta
Incidence
Abdominal Aortic Aneurysm
Dyslipidemias
Walking
Extremities
Outcome Assessment (Health Care)
Physicians
Drug Therapy
Therapeutics
Research
Population

Cite this

@article{8dec37b815c1427bad270f0e0a431d34,
title = "Lipid management in people with peripheral artery disease",
abstract = "PURPOSE OF REVIEW: To summarize recent data on the role of dyslipidaemia and the benefit from managing this in people with disease of the abdominal aorta and its peripheral branches (peripheral artery disease, PAD). RECENT FINDINGS: Findings from the Further Cardiovascular Outcomes Research with Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial demonstrate the benefit of intensely lowering low-density lipoprotein-cholesterol (LDL-c) in people with PAD to substantially reduce the incidence of major cardiovascular events (MACE; myocardial infarction, stroke or cardiovascular death) and major adverse limb events (MALE). Despite the evidence of substantial benefits from lowering LDL-c, the uptake of drug therapies to lower LDL-c remains sub-optimal in people with PAD. SUMMARY: Effective methods to educate physicians and patients on best medical management are needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid therapies for PAD-specific problems like abdominal aortic aneurysm progression and walking impairment. Other novel lipid therapies, such as those that lower lipoprotein (a), maybe particularly beneficial to people with PAD given the evidence indicating high concentrations in this population and the high incidence of MACE in these individuals.",
author = "Jonathan Golledge and Ward, {Natalie C.} and Watts, {Gerald F.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1097/MOL.0000000000000638",
language = "English",
volume = "30",
pages = "470--476",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams & Wilkins",
number = "6",

}

Lipid management in people with peripheral artery disease. / Golledge, Jonathan; Ward, Natalie C.; Watts, Gerald F.

In: Current Opinion in Lipidology, Vol. 30, No. 6, 01.12.2019, p. 470-476.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lipid management in people with peripheral artery disease

AU - Golledge, Jonathan

AU - Ward, Natalie C.

AU - Watts, Gerald F.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - PURPOSE OF REVIEW: To summarize recent data on the role of dyslipidaemia and the benefit from managing this in people with disease of the abdominal aorta and its peripheral branches (peripheral artery disease, PAD). RECENT FINDINGS: Findings from the Further Cardiovascular Outcomes Research with Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial demonstrate the benefit of intensely lowering low-density lipoprotein-cholesterol (LDL-c) in people with PAD to substantially reduce the incidence of major cardiovascular events (MACE; myocardial infarction, stroke or cardiovascular death) and major adverse limb events (MALE). Despite the evidence of substantial benefits from lowering LDL-c, the uptake of drug therapies to lower LDL-c remains sub-optimal in people with PAD. SUMMARY: Effective methods to educate physicians and patients on best medical management are needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid therapies for PAD-specific problems like abdominal aortic aneurysm progression and walking impairment. Other novel lipid therapies, such as those that lower lipoprotein (a), maybe particularly beneficial to people with PAD given the evidence indicating high concentrations in this population and the high incidence of MACE in these individuals.

AB - PURPOSE OF REVIEW: To summarize recent data on the role of dyslipidaemia and the benefit from managing this in people with disease of the abdominal aorta and its peripheral branches (peripheral artery disease, PAD). RECENT FINDINGS: Findings from the Further Cardiovascular Outcomes Research with Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial demonstrate the benefit of intensely lowering low-density lipoprotein-cholesterol (LDL-c) in people with PAD to substantially reduce the incidence of major cardiovascular events (MACE; myocardial infarction, stroke or cardiovascular death) and major adverse limb events (MALE). Despite the evidence of substantial benefits from lowering LDL-c, the uptake of drug therapies to lower LDL-c remains sub-optimal in people with PAD. SUMMARY: Effective methods to educate physicians and patients on best medical management are needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid therapies for PAD-specific problems like abdominal aortic aneurysm progression and walking impairment. Other novel lipid therapies, such as those that lower lipoprotein (a), maybe particularly beneficial to people with PAD given the evidence indicating high concentrations in this population and the high incidence of MACE in these individuals.

UR - http://www.scopus.com/inward/record.url?scp=85074553069&partnerID=8YFLogxK

U2 - 10.1097/MOL.0000000000000638

DO - 10.1097/MOL.0000000000000638

M3 - Article

VL - 30

SP - 470

EP - 476

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 6

ER -